Page 27 - Portuguese Journal - SPORL - Vol 61. Nº2

trials, a recent paper suggested summing protocols in use at their working center
33
the grades of different scales, which could
help in overcoming the anatomic limitations
of each one. A point not mentioned in the
clinical protocol is related to the referral of
comorbidities.
Because CRS with polyposis is often
accompanied by conditions with a type 2
inflammatory component, such as allergic
asthma and hives, these patients clearly
benefit from a multidisciplinary group
consultation (e.g., otorhinolaryngology,
pulmonology, and allergy and immunology).
This aspect is particularly relevant in patients
with CRS with polyposis and comorbid
allergic asthma; for example, patients with
CRS with polyposis without comorbid asthma
who do not respond to dupilumab do not
have a funded therapeutic indication (at the
moment) for omalizumab. However, if they
also have severe persistent asthma, they are
eligible for it.
The clinical protocol presented herein
provides a standardized method for data
collection and proposes inclusion criteria
based on international consensuses for
1,22
the treatment of patients with CRS with
polyposis with biologic agents. It also provides
guidelines for the follow-up of these patients,
with well-defined criteria for continuation and
discontinuation of treatment.
Conclusion
This clinical protocol presents a proposal for
the standardized and uniform collection of
data for use in clinical practice and multicenter
prospective and/or retrospective studies, as
well as a proposal for patient follow-up and
evaluation of the efficacy/failure of treatment
with biologic agents in patients with CRS with
polyposis.
Conflict of interest
The authors declare no conflict of interest
regarding this article.
Data confidentiality
The authors declare that they followed the
regarding the publication of patients’ data.
Funding
Thus study did not receive any contribution,
funding or grant.
Availability of scientific data
There are no publicly available datasets related
to this study.
Bibliographic references
1.Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R,
Reitsma S. et al. European position paper on rhinosinusitis
and nasal polyps 2020. Rhinology. 2020 Feb 20;58(Suppl
S29):1-464. doi: 10.4193/Rhin20.600.
2.Abreu NA, Nagalingam NA, Song Y, Roediger FC,
Pletcher SD, Goldberg NA. et al. Sinus microbiome diversity
depletion and Corynebacterium tuberculostearicum
enrichment mediates rhinosinusitis. Sci Transl Med. 2012
Sep 12;4(151):151ra124. doi: 10.1126/scitranslmed.3003783.
3.Gan W, Yang F, Tang Y, Zhou D, Qing D, Hu J. et al.
The difference in nasal bacterial microbiome diver- sity
between chronic rhinosinusitis patients with polyps
and a control population. Int Forum Allergy Rhinol. 2019
Jun;9(6):582-592.doi: 10.1002/alr.22297.
4.Lee K, Pletcher SD, Lynch SV, Goldberg AN, Cope
EK. Heterogeneity of microbiota dysbiosis in chronic
rhinosinusitis: potential clinical implications and microbial
community mechanisms contributing to sinonasal
inflammation. Front Cell Infect Microbiol. 2018 May
23;8:168. doi: 10.3389/fcimb.2018.00168.
5.Copeland E, Leonard K, Carney R, Kong J, Forer M, Naidoo
Y. et al. Chronic rhinosinusitis: potential role of microbial
dysbiosis and recommendations for sampling sites.
Front Cell Infect Microbiol 2018 Feb 28;8:57. doi: 10.3389/
fcimb.2018.00057.
6.Zhao YC, Bassiouni A, Tanjararak K, Vreugde S, Wormald
PJ, Psaltis AJ. Role of fungi in chronic rhinosinusitis
through ITS sequencing. Laryngoscope. 2018 Jan;128(1):16-
22. doi: 10.1002/lary.26702.
7.Hoggard M, Biswas K, Zoing M, Wagner Mackenzie B,
Taylor MW, Douglas RG. Evidence of microbiota dysbiosis
in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017
Mar;7(3):230-239.doi: 10.1002/alr.21871
8.Karunasagar A, Jalastagi R, Naik A, Rai P. Detection of
bacteria by 16S rRNA PCR and sequencing in culture-
negative chronic rhinosinusitis. Laryngoscope. 2018
Oct;128(10):2223-2225. doi: 10.1002/lary.27122.
9.Chalermwatanachai T, Vilchez-Vargas R, Holtappels
G, Lacoere T, Jáuregui R, Kerckhof FM. et al. Chronic
rhinosinusitis with nasal polyps is characterized by
dysbacteriosis of the nasal microbiota. Sci Rep. 2018 May
21;8(1):7926. doi: 10.1038/s41598-018-26327-2.
10.Lee K, Pletcher SD, Lynch SV, Goldberg AN, Cope
EK. Heterogeneity of microbiota dysbiosis in chronic
rhinosinusitis: potential clinical implications and microbial
community mechanisms contributing to sinonasal
Volume 61 . Nº2 . June 2023 169